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Abstract
Patients with neuropathic pain are heterogeneous in etiology, pathophysiology, and clinical appearance. They exhibit a variety of pain-
related sensory symptoms and signs (sensory profile). Different sensory profiles might indicate different classes of neurobiological
mechanisms, andhence subgroupswith different sensory profilesmight responddifferently to treatment. The aimof the investigationwas
to identify subgroups in a large sample of patients with neuropathic pain using hypothesis-free statistical methods on the database of 3
large multinational research networks (German Research Network on Neuropathic Pain (DFNS), IMI-Europain, and Neuropain).
Standardized quantitative sensory testing was used in 902 (test cohort) and 233 (validation cohort) patients with peripheral neuropathic
pain of different etiologies. For subgrouping, we performed a cluster analysis using 13 quantitative sensory testing parameters. Three
distinct subgroupswith characteristic sensory profileswere identified and replicated.Cluster 1 (sensory loss, 42%) showeda loss of small
and large fiber function in combination with paradoxical heat sensations. Cluster 2 (thermal hyperalgesia, 33%) was characterized by
preserved sensory functions in combination with heat and cold hyperalgesia and mild dynamic mechanical allodynia. Cluster 3
(mechanical hyperalgesia, 24%)was characterizedby a loss of small fiber function in combinationwith pinprick hyperalgesia anddynamic
mechanical allodynia. All clusters occurred across etiologies but frequencies differed. We present a new approach of subgrouping
patients with peripheral neuropathic pain of different etiologies according to intrinsic sensory profiles. These 3 profiles may be related to
pathophysiological mechanisms and may be useful in clinical trial design to enrich the study population for treatment responders.
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1. Introduction
Neuropathic pain syndromes develop after a lesion or disease
affecting the somatosensory nervous system.22,58 Despite
advances in understanding the complex neurobiology of pain,
the pharmacological management of these syndromes
remains insufficient and several promising drugs have failed
in late-stage development.21,35 Thus, there is a need to predict
treatment responders both for clinical practice, in which even
first-line treatments are beneficial in less than 50% of patients,
and for clinical trial design, in which a negative outcomemay be
due to a low responder rate rather than uniform inefficacy of the
treatment.
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Although all neuropathic pain disorders have a common
denominator, ie, damage of the somatosensory nervous system,
the underlying etiologies and pathogeneses of these damages
are distinct. Furthermore, the patterns of sensory signs and
symptoms that develop after neuropathy vary between the
different etiologies and even between individual patients with
neuropathies of the same etiology.5,40 The expression of these
sensory signs, the mosaic of hyperalgesia, allodynia, and sensory
loss, which we call the individual somatosensory profile, reflects
pathophysiological mechanisms in damaged and surviving
afferent nerve fibers such as conduction block, ectopic impulse
generation, peripheral sensitization, and central sensitization.10
Historically, neuropathic pain has been classified, investigated
in clinical trials, and treated on the basis of the underlying etiology.
However, recognising the heterogeneity of pain mechanisms
other classification schemes might be more appropriate.2,64
Thus, an entirely different strategy in which pain is differentiated
on the basis of the underlying mechanisms has been proposed
emphasizing the rationale for a treatment approach directed at
mechanisms rather than diseases.30,34,44,66
Pathophysiological mechanisms of pain generation cannot be
readily examined in patients. Nevertheless, the expression of
some sensory signs can be related to mechanisms, eg, heat
hyperalgesia to peripheral sensitization36 and pinprick hyper-
algesia to central sensitization.6,55 Thus, the individual somato-
sensory profile may reveal some clues of pathophysiological
dysfunctions of afferent processing.5,40
The aim of this investigation was to identify patient subgroups
with distinct sensory profiles in a large sample of patients with
neuropathic pain from a wide range of etiologies collected in 3
multinational research networks. Instead of testing previously
published hypotheses of associations between sensory profiles
and mechanisms, this large data set enabled us to apply
hypothesis-free statistical segmentation methods. This way we
explored the intrinsic patterning of sensory profiles in a represen-
tative spectrum of patients with peripheral neuropathic pain. The
number and type of intrinsic patterns—if reproducible—can then
be related back to pathophysiological and pharmacological
mechanisms in future studies.
We used a standardized protocol of quantitative sensory
testing (QST) in patients with peripheral neuropathic pain of
different etiologies with the following aims:
(1) to describe and analyse typical patterns of sensory signs in
more than 900 patients,
(2) to subgroup the patients on the basis of characteristic sensory
profiles,
(3) to establish a sensory profile-based organizing principle of
neuropathic pain, and
(4) to replicate the results in a second independent cohort of more
than 200 patients.
2. Materials and methods
2.1. Consortia
Three large multinational consortia collected phenotypic data of
patients with peripheral neuropathic pain (test cohort): the
German Research Network on Neuropathic Pain (DFNS), the
EUROPAIN, and the NEUROPAIN collaboration. The gathered
data comprised demographic, psychometric, and clinical data as
well as results of a standardized quantitative sensory assessment
that were captured in one joined central database of the DFNS.40
Each study center used a computer-assisted program for
data entry locally in each center (Neuroquast, Statconsult,
Magdeburg, Germany). For data export into the central database,
a special data export file was created, encrypted, and sent to the
central database through e-mail. All centers and investigators
underwent a strict quality assessment and certification process to
allow future pooling of data across sites and countries.39,63 A
confirmatory analysis of heterogeneity between the participating
centers in healthy subjects and patients painful neuropathies
showed a high degree of homogeneity between the different
centers, making it possible to analyze the database as
a homogenous group.62
The DFNS (http://www.neuropathischer-schmerz.de) was
established to investigate mechanisms and treatments of
neuropathic pain and consists of 10 German centers. The study
protocol was approved by the ethics committee of the University
Hospital Kiel, Germany, and subsequently by the ethics
committees of all participating centers. The EUROPAIN consor-
tium (http://www.imieuropain.org) consists of academic study
groups working on pain research from Germany, Denmark, and
the United Kingdom, a Spanish SME and Europe’s most active
pharmaceutical companies working in the pain field. The ethics
committees of each center approved the study protocol in-
dividually. The NEUROPAIN project is an investigator-initiated
project (sponsored by Pfizer Ltd) consisting of several research-
ers in the field of neuropathic pain research within Europe
(principle investigator [R.B.]) and aims to characterize subgroups
of patients with neuropathic pain. The ethics committees of each
participating center approved the study protocols individually.
2.2. Inclusion criteria
Patients with peripheral neuropathic pain of several etiologies
(polyneuropathy [PNP], peripheral nerve injury [PNI], postherpetic
neuralgia [PHN], and radiculopathy [RAD]) were included
(Table 1).
2.2.1. German Research Network on Neuropathic Pain
Patients were included when the following criteria for each
respective diagnosis were fulfilled:
(1) polyneuropathy: according to the clinical criteria published by
England et al.18 Peripheral nerve injury: presence of somato-
sensory signs in the innervation territory of the injured nerve
according to clinical examination and/or sensory neurography.
Postherpetic neuralgia: presence of neuropathic pain for more
than 3 months in the affected area after healing of the acute
herpes zoster rash. Radiculopathy: history of nerve root
damage and consistent neurological findings.
Table 1
Patient characteristics.
Original data set Validation data set P
Age, y 58 6 14 57 6 14 0.834
Female, n (%) 429/902 (48) 97/233 (42) 0.106
Pain
Current 6.0 6 3.1 5.9 6 2.1 0.275
Duration ,1 y 193/902 (21%) 39/233 (17%) 0.116
Duration .5 y 201/902 (22%) 46/233 (21%) 0.402
Aetiology ,0.001
Polyneuropathy 512/902 (57%) 113/233 (48%)
Peripheral nerve injury 227/902 (25%) 110/233 (47%)
PHN 88/902 (10%) 10/233 (4%)
Radiculopathy 75/902 (8%) —
P values are given for the chi-square approximate test or analysis of variance.
PHN, postherpetic neuralgia.
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2.2.2. Europain and Neuropain consortia
The main inclusion criterion was recurrent or ongoing peripheral
neuropathic pain with a pain intensity $3 (Numerical Rating
Scale, 0-10). Special inclusion criteria for each diagnosis and type
of pain were as follows:
polyneuropathy: pathological nerve conduction studies or
pathologically decreased vibration detection threshold (VDT) at
2 of 4 sites (,5/8) at the lower limb,33,42 which could not be
explained by another disease or pain with PNP-type of location
and evidence of small fiber neuropathy based on skin punch
biopsy, laser-evoked potentials, or bedside thermal testing,
which could not be explained by another disease.
Peripheral nerve injury: history of traumatic nerve injury of the
distal upper or lower limb and sensory motor abnormalities
confined to the innervation territory of the injured nervous
structure.
Postherpetic neuralgia: unilateral zoster rash in the facial or
thoracic area with postzoster scarring, hypopigmentation, or
hyperpigmentation in the affected dermatome or sensory deficit
in the area of the previous zoster rash determined by bedside
testing.
Radiculopathy: pain in the L5 and/or S1 dermatome and
positive straight leg raising test or sensory deficit within the
matching dermatome or diminished Achilles tendon reflex for S1
lesions and magnetic resonance imaging of the lumbar spine
confirming nerve root impairment by a herniated intervertebral
disk or electromyography showing denervation in the L5 or S1
territory.
2.3. Exclusion criteria
Patients with trigeminal neuralgia, central neuropathic pain, and
complex regional pain syndromes were excluded because it is
believed that the underlying pathophysiological mechanisms are
distinct from classical peripheral neuropathic pain etiologies.
Further exclusion criteria were age ,18 years, missing informed
consent, communication problems, pain treatment by topical local
anaesthetics for $7 days in the last 4 months or by topical
capsaicin in the last 6 months, other pain locations with pain
intensities $6 on $15 d/mo, other severe systemic or focal
diseases of the central nervous system, spinal canal stenosis,
peripheral vascular disease, pending litigation, major cognitive or
psychiatric disorders, and treatment with an effect on neuropathic
pain for any conditions except the inclusion criterion. By the latter
criterion, we intended to assure that pain was the leading
diagnosis and not depression. Because patient selection was
done by each individual center, we do not know how many
patientswere excluded for this reason. Data sets were excluded in
case of incomplete records (eg, no precise diagnosis docu-
mented, more than one QST variable missing in the affected area,
no information about age, sex, or other demographic data) (Fig. 1).
All subjects signed written informed consent according to the
Declaration of Helsinki for participation in the respective study and
for transfer of the study records into the central database. The
ethics committee of each center approved the study protocol
individually. The study is reported according to the STROBE
statement. Several centers contributed to more than one
consortium, which contributed to uniform clinical standards
across consortia.
2.4. Quantitative sensory testing and questionnaires
To assure process quality of QST, the investigators of each center
underwent standardized training courses for the performance of
QST.63 The standardized protocol of DFNS was used for QST as
described in detail previously.51,62
Quantitative sensory testing was conducted at themost painful
site within the affected body area (test area) and the mirror-image
contralateral area (control area). In cases of PNP, the cheek was
assessed as the control area. The procedure started with a brief
demonstration of each test in an area not to be included in the
actual QST assessment, followed by QST of the control area and
then QST of the test areas.4
The QST assessed the function of small and large afferent
fibers. The standardized assessment contained 13 different
thermal and mechanical tests. The following parameters were
tested: thermal detection thresholds for the perception of cold
(cold detection threshold [CDT]) and warmth (warm detection
threshold [WDT]), paradoxical heat sensation (PHS) during the
procedure of alternatingwarmand cold stimuli (TSL), thermal pain
thresholds for cold (cold pain threshold [CPT]) and hot stimuli
(heat pain threshold [HPT]), mechanical detection thresholds
(MDT) for touch and vibration (VDT), mechanical pain sensitivity
(MPS) including thresholds for pinprick (mechanical pain thresh-
old [MPT]) and blunt pressure (pressure pain threshold [PPT]),
a stimulus–response–function for pinprick sensitivity (MPS) and
dynamic mechanical allodynia (dynamic mechanical allodynia
[DMA]), and pain summation to repetitive pinprick stimuli (wind-up
ratio [WUR]). For all parameters, negative (loss of function) and
positive (gain of function) phenomena were assessed.
In the DFNS, the German version of the Center for Epidemi-
ological Studies—Depression (CES-D48) was used for assess-
ment of depression, in Neuropain, the Hospital Anxiety and
Depression Scale (HADS71). Within the DFNS, the Neuropathic
Pain Scale (NPS25) was used, in Europain and Neuropain, the
Neuropathic Pain Symptom Inventory (NPSI9). Two items are
highly comparable in these questionnaires, describing the
stabbing and burning quality of spontaneous pain.
2.5. Statistical analyses
2.5.1. Z transformation and quantitative sensory testing
profiles
In a control group of normal volunteers,39,47,51 cold pain, HPTs,
and VDTs as well as the numbers of PHSs during the TSL
procedure were normally distributed. All other parameters were
normally distributed in log space and were transformed
logarithmically before statistical analysis. To compare individual
QST data of patients or of a group of patients with age- and sex-
matched control data, standard normal distributions of the
patient data were calculated for each individual QST variable
(z transformation, exception PHS and DMA). The calculation
was based on measurements in 180 healthy controls.51 Z
scores of zero represent a value corresponding precisely to the
mean of the healthy control cohort, z scores above “0” indicate
a gain of function when the patient wasmore sensitive to the test
stimuli compared with controls (hyperaesthesia or hyperalge-
sia), whereas z scores below “0” indicate a loss of function
referring to a lower sensitivity of the patient (hypoaesthesia or
hypoalgesia). Paradoxical heat sensation and DMA normally do
not occur in healthy subjects. Thus, z transformation was not
possible for these parameters because one would divide by
zero. For PHS and DMA percentages are plotted against original
data: occurrences of PHS (0-3), log numerical ratings scale for
DMA (0-100), and are inserted on the right side of the sensory
profile (Fig. 2).
By this procedure, sensory profiles of an individual patient or
a group of patients can be displayed graphically on one common
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scale of sensory gain or loss as well as the 95% confidence
interval for healthy subjects.
2.5.2. Subgrouping of patients by cluster analysis
A cluster analysis was performed to unravel different and
distinguishable subgroups of patients who are characterized by
typical QST profiles. The 11 z-transformed QST variables (WDT,
TSL, CPT, HPT, PPT, MPT, MPS, WUR, MDT, CDT, and VDT)
were the primary basis for the analysis. In addition, PHS was
transformed to a binary 0/2-variable showing absence (coded as
0) or presence (coded as 12) of pathological values; this puts
PHS into similar metrics as the 11 z-transformed variables where
1.96 SD above or below the reference data mean of z 5 0 is
considered abnormal, and PHS is abnormal except for the lower
extremity in older males. Dynamic mechanical allodynia occurred
in a wide range of intensity values. By comparing the log-intensity
scores with the impact of DMA on the quality of life of the patients,
it was useful to use 3 different intensity levels. According to these
observations, DMA was transformed to a 0/2/3-variable repre-
senting no DMA (coded as 0), DMA with average pain ratings
below 1 (coded as 12), and DMA with average pain ratings
between 1 and 100 (coded as 13). Accordingly, all 13 variables
had a similar metric of means and variances, and we could use
the squared Euclidian distance as the distance measure giving
equal weight to all QST variables.
Because our data set is not computationally challenging, we
used the widely known clustering algorithm k-means as the
primary hypothesis-free analysis tool that divides the data set into
a predetermined number of k clusters.38 The transformed DMA
and PHS variables were included into this procedure, because
the Euclidian distance is a meaningful distance measure for
a dichotomous or trichotomous variable. To make the cluster
analysis completely hypothesis-free, we did not make any a-priori
assumptions about the expected number of clusters. Instead, we
performed k-means analyses for k ranging from 2 to 10 and used
a series of well-established quality criteria from differing
mathematical background to determine the optimum number of
clusters:
(1) As a measure of fragmentation of the k-means solution for
a given number of k clusters, mean silhouette width per cluster
and the number of negative silhouette widths were used to
Figure 1. CONSORT flowchart for test data set. For cluster analysis of sensory profiles in patients with peripheral neuropathic pain, databases from 3 consortia
were combined: German Research Network on Neuropathic Pain (DFNS) (shaded in red), IMI-Europain, and Neuropain (shaded in blue). CRPS, complex regional
pain syndrome; DB, database.
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exclude solutions that are likely to be artificial. Silhouette widths
that range between21 and11 for each patient in the analysis
may indicate that clusters overlap by a small degree of negative
values.52 A high count of negative silhouettes or a cluster with
a mean silhouette width below zero indicates a cluster solution
that is highly fragmented. Thus, we excluded all solutions with
at least 1 cluster with a negative mean silhouette width, or over
10% negative silhouette widths.
(2) To validate a solution that is not dependent on the clustering
method, the remaining k-means solutions were compared with
a robust hierarchical agglomerative clustering method (maxi-
mum linkage) and an expectation maximization (EM) algo-
rithm.15 We compared both solutions with the initial k-means
clustering through the adjusted rand index (ARI) and the
adjusted variation of information (AVI). Although the ARI
measures similarity on a scale from 0 to 1 (high values are
preferable), the AVI measures dissimilarity on the same scale
(low values are preferable49).
(3) The final criterion for the decision between otherwise equally
good k-means solutions with different numbers of clusters was
the Bayesian information criterion (BIC), which captures the
gain of information by an increased number of clusters. The
higher number of clusters is preferable if the difference
between the BICs of both solutions (delta-BIC) is .10.53
2.6. Validation data set
For external validation, patients with PNP, PNI, and PHN who
were collected either within the DFNS after the database closure
in 2010 (n 5 143) or within the Europain consortia for treatment
studies with oxcarbazepine and lidocaine (n 5 90)13,14 (not
included in the flowchart, Fig. 1). Inclusion and exclusion criteria
for the patients collected within the DFNS were identical to the
criteria for the test data set. Inclusion and exclusion criteria for the
patients collected within Europain were identical except that
patients did not fill out questionnaires on pain qualities, de-
pression, and pain course over the last 4 weeks. Test and
validation data sets were equal in age, sex, pain duration, and
current pain intensity. After transforming the individual QST
values into z scores, a separate cluster analysis was performed
within this data set.
3. Results
3.1. Patients
In total, 1848 data sets were included into the combined DFNS/
Europain/Neuropain database. After applying the inclusion/
exclusion criteria, we could assess 902 patients with peripheral
neuropathic pain of different etiologies in the test cohort (Fig. 1).
The validation cohort consisted of 233 patients. Demographic
data of the entire patient cohort are shown in Table 1. Most of the
patients had long-lasting chronic pain between 1 and 5 years.
Pain intensity generally was moderate to severe with average
current pain ratings close to 6 on a 0-to-10 Likert scale without
relevant differences between the cohorts. Distributions of
etiologies differed between the 2 cohorts because of the absence
of patients with RAD in the validation cohort. Questionnaires were
available from 724 of the 902 patients in the test cohort, but not
from the validation cohort.
3.2. Cluster analysis
We used a distributive cluster analysis technique (k-means) that
separates data sets for maximal similarity within clusters and
dissimilarity between clusters in a multidimensional space (here:
13dimensions) for a predeterminednumber of clusters. Therefore,
the first step was to identify the optimal number of clusters in
a data-driven manner (Table 2). We compared k-means cluster
solutions for 2 to 10 clusters. According to the frequency of
negative silhouette widths, we excluded the solutions with 4 to 10
clusters because they each presented at least 1 cluster with
Figure 2. Sensory profiles of the 3-cluster solution for test and replication
data sets. Sensory profiles of the 3 clusters presented as mean z scores6 95%
confidence interval for the test data set (n 5 902, A) and the validation data
set (n5 233, B). Note that z transformation eliminates differences due to test
site, sex, and age. Positive z scores indicate positive sensory signs
(hyperalgesia), whereas negative z values indicate negative sensory signs
(hypoaesthesia and hypoalgesia). Dashed lines: 95% confidence interval for
healthy subjects (21.96 , z , 11.96). Note that if the mean of a cluster is
within the shaded area, this does not imply that it does not differ from
a healthy cohort. Values are significantly different from those of healthy
subjects, if their 95% confidence interval does not cross the zero line. Insets
show numeric pain ratings for dynamic mechanical allodynia (DMA) on
a logarithmic scale (0-100) and frequency of paradoxical heat sensation
(PHS) (0-3). Blue symbols: cluster 1 “sensory loss” (42% in A and 53% in B).
Red symbols: cluster 2 “thermal hyperalgesia” (33% in A and B). Yellow
symbols: cluster 3 “mechanical hyperalgesia” (24% in A and 14% in B). CDT,
cold detection threshold; CPT, cold pain threshold; HPT, heat pain
threshold; MDT, mechanical detection threshold; MPS, mechanical pain
sensitivity; MPT, mechanical pain threshold; NRS, Numerical Rating Scale;
PPT, pressure pain threshold; QST, quantitative sensory testing; TSL,
thermal sensory limen; VDT, vibration detection threshold; WDT, warm
detection threshold; WUR, wind-up ratio.
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a negative mean silhouette width that indicated an artifact.
Furthermore, in each of these solutions, negative silhouettes were
frequent (15%-23%). The remaining 2 and 3 cluster solutionswere
comparedwith 2mathematically different clustering algorithms for
the same number of clusters. Compared with agglomerative
hierarchical cluster analysis, both 2- and 3-cluster solutions were
equal according to the ARI criterion, but the 3-cluster solution was
better according to the AVI criterion. In comparison to the EM
algorithm, the 2-cluster solution failed to show similarity between
k-means and EM clustering (ARI almost zero, AVI almost 1).
Because the delta-BIC also strongly preferred the 3-cluster
solution (Table 2), the 3-cluster solution was used for further
analysis as the optimal number of clusters. This array of
techniques gave multiple lines of converging evidence that
patients should be grouped in exactly 3 clusters.
3.3. Sensory profiles of the 3-cluster solution
Figure 2 shows themean z-score sensory profiles for the test data
set (Fig. 2A) and the replication data set, which was also subjected
to a k-means cluster analysis with k5 3 (Fig. 2B). In both data sets,
the clusters represented similar percentages of patients: cluster 1
was the largest (42% inA, 53% inB), followedbycluster 2 (33% inA
and B), and cluster 3 (24% in A, 14% in B). Sensory profiles were
also replicated excellently. For nonnociceptive temperature sen-
sation (CDT, WDT, and TSL), clusters 1 and 3 exhibited
pronounced deficits with mean z scores near 22, whereas
temperature sensation was essentially normal in cluster 2. This
offset was similar for thermal pain sensitivity (CPT and HPT), but
here clusters 1 and 3 exhibited less of a deficit, whereas cluster 2
exhibited significant sensory gain. Cluster 2was therefore given the
label “thermal hyperalgesia.” For mechanical pain perceptions
(PPT, MPT, and MPS), the rank order between clusters was
different and cluster 1 and 3 were separated: although there was
again a deficit for cluster 1, cluster 3 exhibited significant sensory
gain. Cluster 3 was therefore given the label “mechanical hyper-
algesia.” Wind-up did not differentiate between clusters. For
nonnociceptive touch sensation (MDT and VDT), cluster 2 was
again close to normal, cluster 3 had some deficit, and cluster 1
exhibited the most pronounced deficit. Cluster 1 was given the
label “sensory loss,” because it was characterized by negative
mean z scores across all QST parameters. Dynamic mechanical
allodyniawasmost pronounced in cluster 3,which also exhibits the
most pronounced hyperalgesia to pinprick (MPT and MPS) and
blunt pressure (PPT). Paradoxical heat sensations were most
pronounced in cluster 1, associatedwith diminished cold detection
(CDT) but not cold hyperalgesia (CPT).
Figure 3 illustrates the distinction of the 3 clusters in a 2-D
scatter plot of those 2 QST parameters that exhibited the best
separation of clusters: WDT and MPS. Patients in cluster 1 had
loss of pinprick sensitivity, whereas those in cluster 3 had pinprick
Table 2
Determination of the number of clusters.
n (clusters) 2 3 4 5 6 7 8 9 10
*Mean silhouette width 0.29 0.25 0.23 0.20 0.15 0.17 0.19 0.19 0.21
†Minimum mean silhouette width per cluster 0.28 0.13 20.24 20.28 20.10 20.07 20.003 20.02 20.06
‡Negative silhouettes, % 0.7 4.8 14.5 16.4 22.6 21.2 16.3 16.0 14.7
§Comparison with hierarchical: ARI 0.30 0.30
‖Comparison with hierarchical: AVI 0.67 0.56
§Comparison with EM: ARI 0.01 0.22
‖Comparison with EM: AVI 0.95 0.69
{Comparison with EM: delta-BIC 0 708
Mean silhouette width per cluster below zero indicates clusters that do not separate from other clusters (4-10 cluster solutions).
* Measure of discriminatory power (0-1). 0: no discrimination, 1: perfectly separated clusters (high values are preferred).
† Measure of fragmentation of solution (21 to 11). 21: cluster that is solely a fragment, 11: a solution that is not fragmented (solutions with values below zero were discarded).
‡ Measure of fragmentation of solution (0%-100%). 0%: no fragmentation, 100% a completely fragmented solution (solutions with values above 10% were discarded).
§ ARI (adjusted rand index): measure of similarity (0-1). 0: only random identity, 1: perfect identity (high values are preferred).
‖ AVI (adjusted variation of information): measure of dissimilarity (0-1). 0: no dissimilarity, 1: strong dissimilarity (low values are preferred).
{ Delta-BIC (Bayesian information criterion): measure of gain of information by increasing the cluster number. If delta-BIC .10, the higher cluster number is recommended.
EM, expectation maximization.
Figure 3.Cluster separation projected onto 2-dimensional space. Scatter plot
of the 2 quantitative sensory testing (QST)-parameters that gave the best
cluster separation: mechanical pain sensitivity (MPS) plotted against warm
detection threshold (WDT). Blue dots: cluster 1 “sensory loss” (n 5 381
patients); red dots: cluster 2 “thermal hyperalgesia” (n5 302 patients); yellow
dots: cluster 3 “mechanical hyperalgesia” (n 5 219 patients). Circles indicate
centroids of each cluster.
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hyperalgesia. Most patients in cluster 2 had WDT within the
normal range of61.96 z values, whereas many of clusters 1 and
3 had hypoaesthesia to warmth (z values below21.96). Although
the k-means cluster separation was calculated in 13-dimensional
space, this 2-D projection illustrates some of the main character-
istics how the 3 clusters differ between each other. Partial overlap
between clusters may also be due to 2 mechanisms present in
the same patient.
3.4. Patient characteristics of the 3 clusters
The patients’ sex and mean age did not differ between the 3
clusters (Table 3). The pain intensity also did not differ between
the 3 groups. Depressive symptoms occurred significantly more
frequently in the “sensory loss” cluster. Spontaneous pain
described by the patients as “stabbing” was comparable across
the clusters, but “burning” pain was significantly more frequent in
the “mechanical hyperalgesia” cluster and hence cannot be taken
as evidence for heat hyperalgesia. Information on current
medication of the patients is available only from Europain and
Neuropain (Table 3). Patients in the group “sensory loss” most
frequently took tricyclic antidepressants who also presented an
increased frequency of depressive symptoms. Anticonvulsants
were most frequently taken in the “thermal hyperalgesia” group at
least partly matching to the finding that Na-channel anticonvul-
sants are more effective in a very similar subgroup (“irritable
nociceptor,” see 4.4.14). Importantly, no specific drug was
present in more than half of the patients in any group that shows
that the sensory patterns do not result from drug effects.
Furthermore, when cluster analyses were applied in the 2 largest
groups of medication (tricyclic antidepressants, anticonvulsants),
3 clusters with similar pattern emerge (data not shown).
According to the published DFNS reference data, each QST
parameter in each patient can be individually rated as within or
outside the 95% CI of variability in healthy age- and sex-matched
subjects. This analysis is presented in Figure 4. Of patients in
cluster 1 (“sensory loss”), more than 50% had significant
nonnociceptive sensory loss on an individual basis. Paradoxical
Table 3
Cluster characteristics and medication.
Sensory
loss
Thermal
hyperalgesia
Mechanical
hyperalgesia
Original data set* 381 (42) 302 (33) 219 (24)
Age, y 59 6 14 56 6 14 59 6 15
Female* 169 (39) 152 (35) 108 (25)
Depression* 104 (47)‡ 69 (31) 49 (22)
Pain intensity† 6.1 6 3.1 5.8 6 3.2 6.1 6 3.0
Burning pain† 4.5 6 3.4 4.3 6 3.3 5.1 6 3.2‡
Stabbing pain† 4.7 6 3.2 4.3 6 3.2 5.0 6 3.0
Medication§ 126 (86)‡ 64 (71) 62 (78)
NSAID 28 (19) 18 (20) 13 (16)
SNRI 16 (11) 6 (7) 12 (15)
TCA 60 (41)‡ 20 (22) 21 (26)
Anticonvulsant 41 (28) 34 (38)‡ 20 (25)
Opioid 36 (25) 20 (22) 20 (25)
Validation data set* 124 (53) 77 (33) 32 (14)
Importantly, no specific drug was present in more than half of the patients in any cluster, which shows that the
sensory patterns do not result from drug effects.
* n (%).
† Rated on a 0-to-10 Numerical Rating Scale scale.
‡ P , 0.05.
§ This information is available for n 5 316 patients.
NSAID, nonsteroidal anti-inflammatory drug; SNRI, serotonin-norepinephrine-reuptake-inhibitor; TCA,
tricyclic antidepressant.
Figure 4. Frequencies of abnormal quantitative sensory testing (QST) findings
for the test data set (n 5 902). Each column gives the percentage of patients
with abnormal findings for that particular QST parameter (outside the 95%CI of
healthy subjects). Positive values indicate positive sensory signs (hyper-
algesia), whereas negative values indicate negative sensory signs (hypoaes-
thesia andhypoalgesia).Dashed lines: Expected value for healthy subjects (62.5%).
A: cluster 1 “sensory loss” (n5 381 patients), B: cluster 2 “thermal hyperalgesia”
(n 5 302 patients), C: cluster 3 “mechanical hyperalgesia” (n 5 219 patients).
Significant compared with the expected value (2.5%) on *P, 0.05, **P, 0.01,
***P , 0.001. CDT, cold detection threshold; CPT, cold pain threshold; DMA,
dynamic mechanical allodynia; HPT, heat pain threshold; MDT, mechanical
detection threshold; MPS, mechanical pain sensitivity; MPT, mechanical pain
threshold; NRS, Numerical Rating Scale; PHS, paradoxical heat sensation; PPT,
pressure pain threshold; QST, quantitative sensory testing; TSL, thermal sensory
limen; VDT, vibration detection threshold; WDT, warm detection threshold;
WUR, wind-up ratio.
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heat sensation occurred in 40% and sensory loss for pain
sensitivity was also prevalent, although at less than 50%. Patients
of cluster 2, in contrast, exhibited hardly any sensory loss (except
for touch in about 20% of patients), but significant proportions of
patients presented with hyperalgesia to various stimuli. Cold and
heat hyperalgesia were only significant for this cluster, but—
probably at least partly due to the substantial variability of CPT and
HPT in healthy subjects—all percentages were clearly below 50%.
Patients of cluster 3 were characterized by a combination of loss of
detection of nonnociceptive stimuli and hyperalgesia no noxious
stimuli. However, in contrast to cluster 1, the sensory loss was
more pronounced for small fiber function, ie, diminished temper-
ature perception but relatively preserved tactile perception, and
hyperalgesia was present only for mechanical stimuli. Dynamic
mechanical allodynia was present in the majority of these patients.
Because each individual sensory sign was present in less than
100% of patients per cluster, future analysis on assignment of
individual patients to these cluster prototypes will thus also have to
take subclinical sensory abnormalities into account.
3.5. Distribution of clusters across etiologies of peripheral
neuropathic pain
Figure 5 illustrates that in principle, all 3 clusters were distributed
across all 4 etiologies, which demonstrates that the sensory signs
of neuropathic pain that are produced by these etiologies overlap
considerably. Each of the different etiologies, however, showed
a characteristic pattern of sensory profiles. In PNI, patients with
“thermal hyperalgesia” were significantly more frequent (40.1%)
than patients with other sensory profiles. “Thermal hyperalgesia”
was the least frequent in patients with PNP. Patients with diabetic
PNP only very rarely show this sensory profile (20%, cf. Ref. 57)
indicating a predominant progressive dying-back axonal de-
generation in this etiology. Therefore, “sensory loss”was themost
frequent profile in PNP (51.8%) and RAD (42.7%). Patients with
PHN were concentrated in the “mechanical hyperalgesia”
cluster (46.6%).
4. Discussion
We had hypothesized that patients with peripheral neuro-
pathic pain can be grouped into subtypes based on sensory
profiles and that these profiles may reflect neurobiological
mechanisms. According to the concept that damaged and
surviving nociceptors are the key players in the pathophys-
iology of neuropathic pain,10 one might have expected 2
clusters. Cluster analyses suggested that 3 subgroups best
describe patients with peripheral neuropathic pain. All
subgroups occurred in relevant numbers across etiologies,
but frequencies differed between the entities. This 3-cluster
solution and the structure of the sensory profiles could be
reproduced in the validation cohort. It quite nicely matches the
3 subgroups described in smaller studies in patients with PHN
almost 20 years ago.7,20,31,61
4.1. Cluster 1 (sensory loss)
Cluster 1 (42%) was characterized by a loss of small and large
fiber function and the presence of PHSs (Table 4). These
patients did not suffer from sensory gain except a mild DMA in
few patients. About 52% of patients with polyneuropathies fell
into this category indicating dying-back degeneration of nearly
all fiber classes. Interestingly, 43% of patients with painful RAD
demonstrated this sensory pattern, suggesting severe de-
generation of sensory fibers within the affected nerve root.
Paradoxical heat sensation was most frequent, which sug-
gests that it is induced by a loss of afferent input although at
face value, it is a positive sensory sign possibly related to
a central disinhibition process.29,69
The sensory profile is similar to that of a compression nerve
block.7,24,70 It likely represents the “deafferentation” or “painful
hypoesthesia” subgroups described by others.7,20,31,61 The
spontaneous pain was likely due to ectopic action potentials
generated in proximal sites of injured nociceptors,10 eg, in the
dorsal root ganglion or in deafferented central nociceptive
neurons.16,46,54 Laboratory tests for neuropathic pain assess-
ment are likely to show denervation and loss of function
(Table 4).28
4.2. Cluster 2 (thermal hyperalgesia)
Cluster 2 was characterized by relatively preserved large and
small fiber sensory functions in combination with heat and cold
hyperalgesia and only low-intensity DMA. This pattern occurred in
33% of all patients with peripheral neuropathic pain regardless of
etiology. The fact that in one third of all patients the cutaneous
sensory function was relatively well preserved despite docu-
mented nerve damage indicates that peripheral neuropathic pain
may be associated with effective cutaneous regeneration and
sensitized nociceptors.
The sensory profile is similar to that of a UV-B burn lesion27
and is likely due to peripheral sensitization.59 It represents the
“irritable nociceptor” subgroup described by others.13,14,20,45
Sensitized nociceptors are associated with overexpression of
channels and receptors leading to pathological spontaneous
discharges and a lowered activation threshold for thermal (heat
and cold) and mechanical stimuli. Ongoing hyperactivity in
surviving nociceptors may be responsible for ongoing pain10
and may lead to some central sensitization in the spinal cord
dorsal horn, so that tactile stimuli conveyed in A-fibers become
capable of activating central nociceptive neurons. As a result,
mechanical stimuli induce enhanced pain percepts, ie, pinprick
hyperalgesia and DMA.64 Because these types of mechanical
hyperalgesia were only present in about 20% of the patients,
peripheral nociceptor drive obviously does not always
induce central sensitization.60 Structural laboratory tests for
Figure 5. Distribution of the 3 clusters within each neuropathic pain etiology.
Blue bars: cluster 1 “sensory loss” (n 5 381 patients), red bars: cluster 2
“thermal hyperalgesia” (n 5 302 patients), yellow bars: cluster 3 “mechanical
hyperalgesia” (n 5 219 patients). Cluster 1 was most frequent in polyneur-
opathy, cluster 2 in peripheral nerve injury and radiculopathy, and cluster 3 in
postherpetic neuralgia.
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neuropathic pain assessment are likely to be normal, whereas
functional tests may show gain of function (Table 4).28
4.3. Cluster 3 (mechanical hyperalgesia)
Cluster 3 (24%) was characterized by a predominant loss of cold-
and heat-sensitive small fiber function in combination with blunt
pressure hyperalgesia, pinprick hyperalgesia, and marked and
more frequent DMA. Burning pain quality in this cluster was more
prominent than in the other groups, consistent with findings in
Guillain–Barre´ syndrome in which burning pain was associated
with small fiber deficits43 and with the concept of synthetic heat12
rather than peripheral sensitization to heat. The profile was most
commonly present in patients with PHN (47%). It is similar to the
one induced by high-frequency electrical stimulation of the skin
that is capable of inducing spinal long-term potentiation37,50 and
likely equivalent to “neurogenic hyperalgesia” or “central sensi-
tization” subgroups described by others.7,20 Central sensitization
is prominent for mechanical stimuli6,55,59 but not thermal stimuli.
The dissociation of thermal and mechanical hyperalgesias may
be explained by differences in neural signalling of thermal and
mechanical pain that starts with peripheral encoding in distinct
subsets of nociceptors.11,32 Ongoing pain in this subgroup
indicates spontaneous activity in the nociceptive system, which
may originate in the peripheral and/or central nervous system.
Laboratory tests for neuropathic pain assessment are likely to
reflect mild loss of function; few tests are sensitive to reflect
central sensitization (Table 4).28
4.4. Subgrouping identifies responders
Several trials in neuropathic pain have used baselineQST profiling
to identify predictors of treatment response8 that can be
tentatively assigned to the 3 clusters:
Patients with a baseline QST profile similar to our cluster 2
(“heat hyperalgesia”) exhibited a higher efficacy in a prospective
randomized placebo-controlled trial with oxcarbazepine,14 in
a preplanned analysis of a placebo-controlled trial with botulinum
toxin,1 and in a retrospective analysis of a study using topical
capsaicin patches without a placebo arm.41 A retrospective
analysis of a placebo-controlled trial with topical lidocaine
demonstrated lower efficacy.65
Patients with a baseline QST profile similar to our cluster 1
(“sensory loss”) exhibited a higher efficacy in a retrospective
analysis of a placebo-controlled trial with oral opioids.17 A
prospective randomized placebo-controlled trial with oxcarba-
zepine demonstrated lower efficacy.14
Patients with a baseline QST profile similar to our cluster 3
(“mechanical hyperalgesia”) exhibited a higher efficacy in
retrospective analyses of placebo-controlled trials with oral
pregabalin,56 topical lidocaine,65 lamotrigine,23 or intravenous
lidocaine.3
The different pharmacological profiles support the clinical
relevance of our clusters. Our predictions for differential efficacy
of major neuropathic pain medications across clusters are
summarized in Table 4. The size of the difference in treatment
response between clusters remains to be proven in future
prospective trials.
Table 4
Cluster characteristics, hypotheses on underlying pathophysiology, and rational pharmaceutical treatment.
Sensory loss Thermal hyperalgesia Mechanical hyperalgesia
Original data set, n (%) 381 (42) 302 (33) 219 (24)
Validation data set, n (%) 124 (53) 77 (33) 32 (14)
Sensory profile
Sensory loss Touch, thermal, pain None Mostly thermal
Hyperalgesia None Mostly cold and heat Mostly pressure and pin
DMA Little Little Much
PHS Much Little Little
Pathophysiology
Sensory loss Small and large fibres — Mostly small fibres
Hyperalgesia — Mostly peripheral sensitization Mostly central sensitization
Ongoing pain Ectopic activity in damaged nociceptors or in CNS
neurons
Spontaneous activity in surviving nociceptors (Ectopic?) activity in nociceptors
Predicted findings
IENFD Loss None Mild loss
CCM Loss None Mild loss
Peripheral MRI Damage None Mild damage
LEP Reduction Normal or gain Mild reduction
RIII Reduction Normal or gain Gain
mENG Denervation Sensitization Little denervation
Predicted efficacy
NSAIDS — (1) —
Botox 1
Topical capsaicin 1
NMDA-antagonist 1
Antidepressant 11 1 1
Gabapentinoid 1 1 11
Na-channel blocker 1 11 11
Opioid 11 1 1
CCM, confocal corneal microscopy; CNS, central nervous system; DMA, dynamical mechanical allodynia; IENFD, intraepidermal nerve fiber density; LEP, laser evoked potential; NMDA, N-methyl-D-aspartate; PHS, paradoxical
heat sensation; RIII, flexor reflex; mENG, microneurography.
MRI, magnetic resonance imaging.
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4.5. Limitations
Because the inclusion criteria slightly differed between the 3
consortia, there is no perfect homogeneity of patients within
etiologies. Furthermore, in contrast to short-term stability of
QST,26 long-term stability over weeks has not been studied, and
hence it is possible that patients can shift from one cluster into
another. It should be noted that implementation of the DFNSQST
protocol requires formal training, which has been undergone by
about 70 centers around the world so far.
Dynamic QST, ie, assessment of a change of a QST parameter
to an external stimulus,4 is not the focus of our testing protocol.
The only dynamic marker used, WUR, did not distinguish
between subgroups. Another option of dynamic QST, the
conditioned pain modulation, has demonstrated a potential in
response prediction. This paradigm uses the fact that pain
sensitivity is physiologically modulated by monoaminergic
descending pathways originating in the brainstem and projecting
to the spinal nociceptive transmission centers.67 Individuals with
diabetic painful neuropathy with a malfunctioning pain modula-
tion benefit more from duloxetine treatment than do patients with
a normal modulation pattern.68
4.6. Summary and conclusions
Using an unbiased hypothesis-free data segmentation approach
on a broad range of peripheral neuropathic pain diagnoses, we
identified 3 clusters that are consistent with previous smaller
studies in the field, are pathophysiologically plausible, and can be
tentatively related to pharmacological sensitivity. An important
challenge will be to develop an algorithm that assigns individual
patients to one of the clusters described in this study. We
propose a Bayes network that provides probabilities for a patient
to belong to each cluster. Based on this algorithm, future clinical
trials should classify all included patients according to the 3
clusters and test for differential drug efficacy across clusters as
a planned secondary analysis. In case a consistent pattern
emerges, further trials could then use the clusters for stratification
or as an inclusion criterion. The resulting label for a medication
licensed this way is likely to be restricted to the respective cluster
profile, but any disadvantages of this restricted label should be
offset by a higher responder rate. As a result of the presented
data, the European Medicines Agency (EMA) has recently
acknowledged in a “CHMP qualification advice” that sensory
profiling and subgrouping as proposed in this study is an
adequate stratification tool for determining specific sensory
phenotypes of patients in exploratory trials on neuropathic pain.19
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